scholarly journals IMPROVING MORTALITY IN AML IN LOW-TO-MEDIUM-INCOME COUNTRIES (LMIC): THE IMPACT OF SELECTIVE DIGESTIVE TRACT DECONTAMINATION WITH GENTAMYCIN, VORICONAZOLE PROPHYLAXIS AND SINGLE-BED ROOMS

2020 ◽  
Vol 42 ◽  
pp. 156
Author(s):  
B.K.L. Duarte ◽  
A.G.O. Braga ◽  
L.F. Bachur ◽  
L.G.O. Cardoso ◽  
R. Fagnani ◽  
...  
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
David Machover ◽  
Wathek Almohamad ◽  
Vincent Castagné ◽  
Christophe Desterke ◽  
Léa Gomez ◽  
...  

AbstractSupplementation of cancer cells exposed to 5-fluorouracil (FUra) and folinic acid (FA) with high concentration pyridoxal 5′-phosphate, the cofactor of vitamin B6, potentiates the cytotoxicity of FUra in a synergistic interaction mode. We report a pilot study in 13 patients with previously untreated advanced carcinoma of the digestive tract to assess the impact of high-dose pyridoxine (PN) on the antitumor activity of regimens comprising FUra and FA. Five patients had colorectal adenocarcinoma (CRC); 5 had pancreas adenocarcinoma (PC); and 3 had squamous cell carcinoma of the esophagus (EC). Patients with CRC and with PC received oxaliplatin, irinotecan, FUra and FA, and patients with EC had paclitaxel, carboplatin, FUra and FA. PN iv from 1000 to 3000 mg/day preceded each administration of FA and FUra. Eleven patients responded. Two patients with CRC attained CRs and 3 had PRs with reduction rates ≥ 78%. Two patients with PC attained CRs, and 2 had PRs with reduction rates ≥ 79%. Responders experienced disappearance of most metastases. Of 3 patients with EC, 2 attained CRs. Median time to attain a response was 3 months. Unexpected toxicity did not occur. Results suggest that high-dose vitamin B6 enhances antitumor potency of regimens comprising FUra and FA.


2018 ◽  
Vol 06 (12) ◽  
pp. E1470-E1476 ◽  
Author(s):  
Solène Dermine ◽  
Maximilien Barret ◽  
Caroline Prieux ◽  
Sophie Ribière ◽  
Sarah Leblanc ◽  
...  

Abstract Background The recent development of endoscopic resection for superficial gastrointestinal cancers could justify the need for a dedicated oncological multidisciplinary meeting (MDM). The aim of our study was to evaluate the impact of the dedicated MDM on the management of superficial cancers of the digestive tract. Methods A dedicated MDM was developed at our tertiary referral center. A retrospective review of the MDM conclusions for all patients referred from March 2015 to March 2017 was performed. Outcomes measurements were the outcomes of endoscopic resection, and the concordance rate between the MDM recommendations, European Society of Gastrointestinal Endoscopy (ESGE) guidelines, and final patient management. Results In total, 153 patients with a median age of 69 years were included. Half of the patients had major comorbidities. The mean lesion size was 25 mm, and R0 and curative resection rate were 73.9 % and 56.9 %, respectively. Forty-three patients had an indication for surgery after endoscopic resection. The concordance rate between ESGE guidelines and MDM recommendation was 92.2 %, and 12 patients did not receive the treatment recommended due to comorbidities. Conclusion A MDM dedicated to superficial tumors helped tailor the ESGE guidelines to each patient in order to avoid unnecessary surgery.


2013 ◽  
Vol 58 (1) ◽  
pp. 627-627 ◽  
Author(s):  
Teysir Halaby ◽  
Nashwan al Naiemi ◽  
Jan Kluytmans ◽  
Job van der Palen ◽  
Christina M. J. E. Vandenbroucke-Grauls

2012 ◽  
Vol 13 (8) ◽  
pp. 1113-1129 ◽  
Author(s):  
Luciano Silvestri ◽  
Hendrick KF van Saene ◽  
Andy J Petros

Sign in / Sign up

Export Citation Format

Share Document